Ns by differential centrifugation. B and C. Immunoblot analysis of soluble/ insoluble fractions separated by differential centrifugation. FKIPS DCARD stable cells were cultured for 3 h in the absence or presence of AP. Cell lysates were separated by differential centrifugation. FK-IPS DCARD and endogenous MFN1, TRAF6, and actin were detected by immunoblotting. (PDF)Figure S7 Involvement of CARD9 in NF-kB dependent pathway. A. HeLa FK-IPS#48 cells were transfected with N.C. siRNA or CARD9 targeted siRNA for 48 h, and the knockdown of CARD9 was analyzed by RT-PCR. B, C and D. HeLa FKIPS#48 cells were transfected with N.C. siRNA or CARD9 targeted siRNA for 48 h, then mock treated or treated with AP20187 for 3 h. Cellular 
RNA were extracted and analyzed for IFN-b (B), Il-6 (C) or Il-1b (D) mRNA by qPCR. Representative data of at least two independent experiments are shown. Error bars: standard error of triplicated samples. Statistical analyses were conducted with an unpaired t test, with values of p,0.05 considered statistically significant. *p,0.05. (PDF)promoter upon oligomerization. HEK 293T cells were transiently transfected with p-55C1BLuc together with the FK or FK-IPS 400?40 constructs. Cells were treated with or without AP20187 for 6 h. Relative luciferase activities were determined as described in Materials and Methods. A representative result of at least two independent experiments is shown. Error bars indicate standard error of triplicate samples. (PDF)Figure S5 IPS-1D100?00 (mini-MAVS) failed to activateAcknowledgmentsWe are grateful to S. Akira for the IPS-1 deficient MEFs, Z. J. Chen for the plasmid constructs, and D. Chan for MFN1 deficient MEFs.signaling in the absence of endogenous IPS-1. IPS-12/2 or +/+ MEFs were transiently transfected with luciferase reporter plasmid, p-55C1BLuc together with IPS-1(MAVS), IPS-1D100?500 (mini-MAVS), or control vector. Relative luciferase activities were determined as described in Materials and Methods. A representative result of at least two independent experiments is shown. Error bars indicate standard error of triplicate samples. (PDF)Figure S6 Recruitment of TRAF6 into NP-40 insoluble fraction upon oligomerization of IPS-1. A. Scheme forAuthor ContributionsConceived and designed the experiments: ST K. Onoguchi K. Onomoto MY TF. Performed the experiments: ST K. Onoguchi K. Onomoto RN FI TKF. Analyzed the data: ST K. Onoguchi K. Onomoto RN KT FI MY HK TF TKF. Wrote the paper: ST K. Onoguchi K. Onomoto RN MY HK TF.
It is becoming increasingly apparent that splicing defects play a key role in cancer, and that genomic changes in splicing elements [1?], sometimes termed “splicing spoilers” [4,5], can promote aberrant splicing. Because regulation of splicing is such a complex network [1,4], all genetic variations in genomic DNA and premRNA should be evaluated for their impact on splicing within any given genomic context. It has been estimated that ,50 of mutations underlying genetic diseases cause aberrant splicing [6]. 64849-39-4 site Alterations in a splicing site or splicing control region can have long range implications for splicing events, including altered 3-D architecture of pre-mRNA, activation of cryptic splice sites, exclusion of exons and/or inclusion of all or part of introns. 58-49-1 chemical information single mutations can strengthen otherwise weak splice sites and discriminate against otherwise strong splice sites [2?]. Defective mRNA splicing caused by single nucleotide polymorphisms (SNPs) and/or splice site mutatio.Ns by differential centrifugation. B and C. Immunoblot analysis of soluble/ insoluble fractions separated by differential centrifugation. FKIPS DCARD stable cells were cultured for 3 h in the absence or presence of AP. Cell lysates were separated by differential centrifugation. FK-IPS DCARD and endogenous MFN1, TRAF6, and actin were detected by immunoblotting. (PDF)Figure S7 Involvement of CARD9 in NF-kB dependent pathway. A. HeLa FK-IPS#48 cells were transfected with N.C. siRNA or CARD9 targeted siRNA for 48 h, and the knockdown of CARD9 was analyzed by RT-PCR. B, C and D. HeLa FKIPS#48 cells were transfected with N.C. siRNA or CARD9 targeted siRNA for 48 h, then mock treated or treated with AP20187 for 3 h. Cellular RNA were extracted and analyzed for IFN-b (B), Il-6 (C) or Il-1b (D) mRNA by qPCR. Representative data of at least two independent experiments are shown. Error bars: standard error of triplicated samples. Statistical analyses were conducted with an unpaired t test, with values of p,0.05 considered statistically significant. *p,0.05. (PDF)promoter upon oligomerization. HEK 293T cells were transiently transfected with p-55C1BLuc together with the FK or FK-IPS 400?40 constructs. Cells were treated with or without 
AP20187 for 6 h. Relative luciferase activities were determined as described in Materials and Methods. A representative result of at least two independent experiments is shown. Error bars indicate standard error of triplicate samples. (PDF)Figure S5 IPS-1D100?00 (mini-MAVS) failed to activateAcknowledgmentsWe are grateful to S. Akira for the IPS-1 deficient MEFs, Z. J. Chen for the plasmid constructs, and D. Chan for MFN1 deficient MEFs.signaling in the absence of endogenous IPS-1. IPS-12/2 or +/+ MEFs were transiently transfected with luciferase reporter plasmid, p-55C1BLuc together with IPS-1(MAVS), IPS-1D100?500 (mini-MAVS), or control vector. Relative luciferase activities were determined as described in Materials and Methods. A representative result of at least two independent experiments is shown. Error bars indicate standard error of triplicate samples. (PDF)Figure S6 Recruitment of TRAF6 into NP-40 insoluble fraction upon oligomerization of IPS-1. A. Scheme forAuthor ContributionsConceived and designed the experiments: ST K. Onoguchi K. Onomoto MY TF. Performed the experiments: ST K. Onoguchi K. Onomoto RN FI TKF. Analyzed the data: ST K. Onoguchi K. Onomoto RN KT FI MY HK TF TKF. Wrote the paper: ST K. Onoguchi K. Onomoto RN MY HK TF.
It is becoming increasingly apparent that splicing defects play a key role in cancer, and that genomic changes in splicing elements [1?], sometimes termed “splicing spoilers” [4,5], can promote aberrant splicing. Because regulation of splicing is such a complex network [1,4], all genetic variations in genomic DNA and premRNA should be evaluated for their impact on splicing within any given genomic context. It has been estimated that ,50 of mutations underlying genetic diseases cause aberrant splicing [6]. Alterations in a splicing site or splicing control region can have long range implications for splicing events, including altered 3-D architecture of pre-mRNA, activation of cryptic splice sites, exclusion of exons and/or inclusion of all or part of introns. Single mutations can strengthen otherwise weak splice sites and discriminate against otherwise strong splice sites [2?]. Defective mRNA splicing caused by single nucleotide polymorphisms (SNPs) and/or splice site mutatio.
